Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti -CD38 antibody drug for treating multiple myeloma - ScienceDirect
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC
CD38 in the age of COVID-19: a medical perspective
RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Ida H Hiemstra's research works Genmab, Copenhagen and other places
RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38
Biology drives the discovery of bispecific antibodies as innovative therapeutics. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
CD38 treatment and PD-1/PD-L1. Nivolumab significantly reduced the
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
de
por adulto (o preço varia de acordo com o tamanho do grupo)
